{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T00:08:28Z","timestamp":1717978108929},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,8]]},"DOI":"10.7759\/cureus.61980","type":"journal-article","created":{"date-parts":[[2024,6,9]],"date-time":"2024-06-09T05:01:35Z","timestamp":1717909295000},"source":"Crossref","is-referenced-by-count":0,"title":["Glecaprevir-Pibrentasvir and Ethinyl Estradiol-Induced Liver Injury in a Patient Without Cirrhosis"],"prefix":"10.7759","author":[{"given":"Jennifer","family":"Wiese","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nayiri A","family":"Derian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shristee","family":"Ghimire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zarna","family":"Bambhroliya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tejas","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2019.08.002","article-title":"Epidemiology, predisposing factors, and outcomes of drug-induced liver injury","volume":"24","author":"Bj\u00f6rnsson ES","year":"2020","unstructured":"Bj\u00f6rnsson ES. Epidemiology, predisposing factors, and outcomes of drug-induced liver injury. Clin Liver Dis. 2020, 24:1-10. 10.1016\/j.cld.2019.08.002","journal-title":"Clin Liver Dis"},{"key":"ref2","unstructured":"Using the guidance on your mobile device. (2022). Accessed. May 30, 2024: https:\/\/www.hcvguidelines.org\/."},{"key":"ref3","unstructured":"Maviret (glecaprevir\/pibrentasvir) 100 mg\/40 mg film-coated tablets. summary of product characteristics. (2017). Accessed: May 30, 2024: http:\/\/www.mavyret.com\/?cid=ppc_ppd_msft_HCV_Branded_hepatitis_c_drug_medicine_glecaprevir_Phrase_USMAVY220222&gclid=...."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2021.2012589","article-title":"Drug-induced liver injury by glecaprevir\/pibrentasvir treatment for chronic hepatitis C infection: a systematic review and meta-analysis","volume":"54","author":"Hung HY","year":"2022","unstructured":"Hung HY, Hung WL, Shih CL, Chen CY. Drug-induced liver injury by glecaprevir\/pibrentasvir treatment for chronic hepatitis C infection: a systematic review and meta-analysis. Ann Med. 2022, 54:108-20. 10.1080\/07853890.2021.2012589","journal-title":"Ann Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000017343","article-title":"A case report of glecaprevir\/pibrentasvir-induced severe hyperbilirubinemia in a patient with compensated liver cirrhosis","volume":"98","author":"Yoon JH","year":"2019","unstructured":"Yoon JH, Kim SM, Kang G, Kim HJ, Jun CH, Choi SK. A case report of glecaprevir\/pibrentasvir-induced severe hyperbilirubinemia in a patient with compensated liver cirrhosis. Medicine (Baltimore). 2019, 98:e17343. 10.1097\/MD.0000000000017343","journal-title":"Medicine (Baltimore)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2018-226622","article-title":"Glecaprevir\/pibrentasvir-associated acute liver injury in non-cirrhotic, chronic HCV infection without HBV co-infection","volume":"12","author":"Hammami MB","year":"2019","unstructured":"Hammami MB, Aboushaar R, Alsabbagh E. Glecaprevir\/pibrentasvir-associated acute liver injury in non-cirrhotic, chronic HCV infection without HBV co-infection. BMJ Case Rep. 2019, 12:e226622. 10.1136\/bcr-2018-226622","journal-title":"BMJ Case Rep"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1055\/s-0042-1750716","article-title":"Acute liver injury due to glecaprevir\/pibrentasvir in a patient with chronic hepatitis C virus infection without cirrhosis","volume":"12","author":"Jain A","year":"2022","unstructured":"Jain A, Mumtaz K. Acute liver injury due to glecaprevir\/pibrentasvir in a patient with chronic hepatitis C virus infection without cirrhosis. Avicenna J Med. 2022, 12:154-6. 10.1055\/s-0042-1750716","journal-title":"Avicenna J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s00204-020-02885-1","article-title":"Drug induced liver injury: an update","volume":"94","author":"Garcia-Cortes M","year":"2020","unstructured":"Garcia-Cortes M, Robles-Diaz M, Stephens C, Ortega-Alonso A, Lucena MI, Andrade RJ. Drug induced liver injury: an update. Arch Toxicol. 2020, 94:3381-407. 10.1007\/s00204-020-02885-1","journal-title":"Arch Toxicol"},{"key":"ref9","article-title":"Mavyret","author":"National Institute of Diabetes and Digestive and Kidney Diseases","year":"2022","unstructured":"National Institute of Diabetes and Digestive and Kidney Diseases. Mavyret. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD; 2022."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.109.026997","article-title":"Further assessment of 17alpha-ethinyl estradiol as an inhibitor of different human cytochrome P450 forms in vitro","volume":"37","author":"Chang SY","year":"2009","unstructured":"Chang SY, Chen C, Yang Z, Rodrigues AD. Further assessment of 17alpha-ethinyl estradiol as an inhibitor of different human cytochrome P450 forms in vitro. Drug Metab Dispos. 2009, 37:1667-75. 10.1124\/dmd.109.026997","journal-title":"Drug Metab Dispos"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.104.000182","article-title":"The involvement of CYP3A4 and CYP2C9 in the metabolism of 17 alpha-ethinylestradiol","volume":"32","author":"Wang B","year":"2004","unstructured":"Wang B, Sanchez RI, Franklin RB, Evans DC, Huskey SE. The involvement of CYP3A4 and CYP2C9 in the metabolism of 17 alpha-ethinylestradiol. Drug Metab Dispos. 2004, 32:1209-12. 10.1124\/dmd.104.000182","journal-title":"Drug Metab Dispos"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/metabo12100931","article-title":"Estradiol, estrone and ethinyl estradiol metabolism studied by high resolution LC-MS\/MS using stable isotope labeling and trapping of reactive metabolites","volume":"12","author":"Chabi K","year":"2022","unstructured":"Chabi K, Sleno L. Estradiol, estrone and ethinyl estradiol metabolism studied by high resolution LC-MS\/MS using stable isotope labeling and trapping of reactive metabolites. Metabolites. 2022, 12:931. 10.3390\/metabo12100931","journal-title":"Metabolites"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/v14030614","article-title":"Four weeks treatment with glecaprevir\/pibrentasvir + ribavirin-a randomized controlled clinical trial","volume":"14","author":"Madsen LW","year":"2022","unstructured":"Madsen LW, Christensen PB, Hansen JF, R\u00f8ge BT, Holm DK, Dr\u00f6se S, \u00d8vrehus A. Four weeks treatment with glecaprevir\/pibrentasvir + ribavirin-a randomized controlled clinical trial. Viruses. 2022, 14:614. 10.3390\/v14030614","journal-title":"Viruses"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/v15020489","article-title":"Risk factors of glecaprevir\/pibrentasvir-induced liver injury and efficacy of ursodeoxycholic acid","volume":"15","author":"Tamai H","year":"2023","unstructured":"Tamai H, Okamura J. Risk factors of glecaprevir\/pibrentasvir-induced liver injury and efficacy of ursodeoxycholic acid. Viruses. 2023, 15:489. 10.3390\/v15020489","journal-title":"Viruses"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31003","article-title":"Short-duration pan-genotypic therapy with glecaprevir\/pibrentasvir for 6 weeks among people with recent hepatitis C viral infection","volume":"72","author":"Martinello M","year":"2020","unstructured":"Martinello M, Orkin C, Cooke G, et al.. Short-duration pan-genotypic therapy with glecaprevir\/pibrentasvir for 6 weeks among people with recent hepatitis C viral infection. Hepatology. 2020, 72:7-18. 10.1002\/hep.31003","journal-title":"Hepatology"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/248801-glecaprevir-pibrentasvir-and-ethinyl-estradiol-induced-liver-injury-in-a-patient-without-cirrhosis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,9]],"date-time":"2024-06-09T05:01:40Z","timestamp":1717909300000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/248801-glecaprevir-pibrentasvir-and-ethinyl-estradiol-induced-liver-injury-in-a-patient-without-cirrhosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,8]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.61980","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,8]]}}}